Early serum albumin decrease of ≥10% from baseline has been identified as a biomarker of poor response to ICI monotherapy in patients with NSCLC, where it may be associated with the metabolic clearance of these agents [47]. This evidence concerns the gene ALB and non-small cell lung carcinoma.